Intec Pharma Ltd. (NASDAQ:NTEC) and Cytori Therapeutics Inc. (NASDAQ:CYTX) compete against each other in the Biotechnology sector. We will contrast them and contrast their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Intec Pharma Ltd.||N/A||0.00||43.54M||-1.40||0.00|
|Cytori Therapeutics Inc.||N/A||0.00||N/A||-3.90||0.00|
Table 1 shows gross revenue, earnings per share and valuation of the two companies.
Table 2 has Intec Pharma Ltd. and Cytori Therapeutics Inc.’s return on assets, return on equity and net margins.
|Net Margins||Return on Equity||Return on Assets|
|Intec Pharma Ltd.||0.00%||0%||0%|
|Cytori Therapeutics Inc.||0.00%||-261.3%||-79.5%|
Insider & Institutional Ownership
Roughly 39.64% of Intec Pharma Ltd. shares are held by institutional investors while 6.8% of Cytori Therapeutics Inc. are owned by institutional investors. Insiders held 11.81% of Intec Pharma Ltd. shares. Competitively, 2.42% are Cytori Therapeutics Inc.’s share held by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Intec Pharma Ltd.||-5.95%||4.85%||37.69%||116.32%||34.75%||9.02%|
|Cytori Therapeutics Inc.||-8.29%||-28.42%||-26.18%||-57.89%||-92.62%||-17.24%|
For the past year Intec Pharma Ltd. has 9.02% stronger performance while Cytori Therapeutics Inc. has -17.24% weaker performance.
Intec Pharma Ltd. beats Cytori Therapeutics Inc. on 4 of the 6 factors.
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The companyÂ’s lead product candidate is Accordion Pill Carbidopa/Levodopa (AP-CDLD), which is in a Phase III clinical trial for the treatment of ParkinsonÂ’s disease symptoms in advanced ParkinsonÂ’s disease patients. It is also developing Accordion Pill Zaleplon (AP-ZP) that is in a Phase III clinical trial for the treatment of insomnia, including sleep induction and for enhancing of sleep maintenance; Accordion Pill, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and Accordion Pill platform with Cannabidiol and 9-Tetrahydrocannabinol, (AP-CBD/THC), which is in a Phase I clinical trial for the treatment of various indications, including low back neuropathic pain and fibromyalgia. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd. in March 2004. Intec Pharma Ltd. was founded in 2000 and is based in Jerusalem, Israel.
Cytori Therapeutics, Inc. develops cellular therapeutics for specific diseases and medical conditions. The company primarily provides Cytori Cell Therapy, which is in Phase III pivotal clinical trial for the treatment of impaired hand function in scleroderma. It also offers Celution System devices, proprietary enzymes, and sterile consumable sets that are used at the point-of-therapeutic application or at an off-site processing center; and StemSource cell and tissue banking systems, as well as surgical accessories and instruments. The company also provides ATI-0918, a liposomal encapsulation of doxorubicin for use in treating breast cancer, ovarian cancer, multiple myeloma, and KaposiÂ’s Sarcoma; and ATI-1123, a liposomal formulation of docetaxel for the treatment of non-small cell lung cancer, breast cancer, squamous cell carcinoma of the head and neck cancer, gastric adenocarcinoma, and hormone refractory prostate cancer. It serves hospitals, clinics, physicians, researchers, and other customers for commercial and research purposes through direct sales force, third-party distributors, independent sales representatives, and partners worldwide. The company was founded in 1996 and is headquartered in San Diego, California.